Venture Capital Investors

Oxford Bioscience Partners

Oxford Bioscience Partners is a VC investing group that backs high-potential tech companies.

Venture Investor Overview

Venture Investor
Oxford Bioscience Partners
Status
InActive
Investor Type
Venture Capital
Activity Level
98 transactions
Funds Raised
Unknown
Industry Focus
Energy & Battery

Contact Information

Contact
Jonathan Fleming
Title
General Partner
Mailing Address
12 Giles Pl. P.O. Box 207
Mansfield, MA 02048
USA
Phone
(617) 357-7474
Website
www.oxbio.com
Email Address
Not Recorded

Background Information

Overview
Oxford Bioscience Partners (OBP) is a life science venture capital firm that provides equity financing and management assistance to advanced-stage start-ups and later-stage commercially oriented organizations. The General Partners of OBP currently manage venture funds with committed capital of more than $800 million.
Profile
Oxford Bioscience Partners LinkedIn Company Profile
Social Media
Oxford Bioscience Partners Company Twitter Account
Company News
Oxford Bioscience Partners News
Facebook
Oxford Bioscience Partners on Facebook
YouTube
Oxford Bioscience Partners on YouTube
Last Transaction
3/31/2014

Transaction History

Our records indicate that Oxford Bioscience Partners invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Company
Date
Amount
Glori Energy
3/31/2014
$5,049,100
Dicerna Pharmaceuticals
8/1/2013
$60,000,000
Glori Energy
6/30/2013
$12,810,000
LUCA Technologies
3/31/2013
$4,000,000
Mitralign
5/16/2012
$35,000,000
Glori Energy
1/26/2012
$20,000,000
superDimension
9/30/2011
$11,000,000
Intrapace
6/30/2011
$60,939,000
ZetaRx Biosciences
12/31/2010
$750,000
Cambridge Endoscopic Devices
12/31/2010
$3,888,000
Dicerna Pharmaceuticals
8/11/2010
$25,000,000
SmartPill
6/30/2010
$7,700,000
Intrapace
6/30/2010
$49,771,000
superDimension
6/30/2010
$9,800,000
Seahorse Bioscience
2/23/2010
$5,000,000
Tragara Pharmaceuticals
2/8/2010
$5,000,000
Molecular Biometrics
1/12/2010
$12,500,000
Glori Energy
12/31/2009
$8,718,000
Cambrios Technologies
11/3/2009
$14,500,000
Coherex Medical
8/20/2009
$16,500,000
Molecular Biometrics
6/30/2009
$2,400,000
Pathway Medical Technologies
5/20/2009
$42,500,000
Elixir Pharmaceuticals
5/19/2009
$12,000,000
VaxInnate
5/6/2009
$30,000,000
Glori Energy
3/31/2009
Unknown
Molecular Biometrics
3/31/2009
$1,500,000
Claros Diagnostics
3/23/2009
$4,000,000
Melinta Therapeutics
2/4/2009
$25,000,000
Coherex Medical
12/31/2008
$7,000,000
Radius Health
11/20/2008
$15,000,000
Molecular Biometrics
11/10/2008
$12,000,000
Pathway Medical Technologies
9/30/2008
$16,500,200
SmartPill
7/22/2008
$20,000,000
VaxInnate
6/30/2008
$20,000,000
ZettaCore
5/30/2008
$22,000,000
Bradford Networks
4/18/2008
$20,000,000
Pathway Medical Technologies
4/15/2008
$24,500,000
AVEO Oncology
12/31/2007
$5,499,600
Decision Biomarkers
12/31/2007
$9,500,000
Mitralign
12/4/2007
$24,000,000
Dicerna Pharmaceuticals
11/14/2007
$13,000,000
Xencor
10/25/2007
$15,000,000
LUCA Technologies
10/10/2007
$14,600,000
Elixir Pharmaceuticals
9/30/2007
$28,030,100
FlowMedica
9/30/2007
$2,600,000
Ensemble Discovery
6/30/2007
$5,000,000
AVEO Oncology
5/3/2007
$53,000,000
Coherex Medical
4/18/2007
$8,525,000
Cambrios Technologies
3/31/2007
$18,500,000
Ensemble Discovery
3/31/2007
$10,000,100
PINT
3/26/2007
$18,000,000
Tragara Pharmaceuticals
3/15/2007
$40,000,000
Claros Diagnostics
1/19/2007
$7,800,000
Radius Health
12/31/2006
$17,860,000
Hydrocision
12/8/2006
$12,700,000
Xanthus Pharmaceuticals
12/1/2006
$25,000,000
Elixir Pharmaceuticals
11/29/2006
$46,000,000
Solstice Neurosciences
11/8/2006
$85,000,000
Pathway Medical Technologies
11/1/2006
$25,000,000
VaxInnate
10/25/2006
$40,000,000
ZettaCore
9/30/2006
$3,000,000
Intrapace
8/14/2006
$30,000,000
Elixir Pharmaceuticals
6/30/2006
$18,400,000
Mitralign
6/30/2006
$13,000,000
Melinta Therapeutics
6/20/2006
$50,000,000
CardioFocus
4/24/2006
$21,500,000
Xanthus Pharmaceuticals
3/31/2006
$10,000,000
Decision Biomarkers
2/3/2006
$7,600,000
Hypnion
12/19/2005
$20,100,000
FlowMedica
11/9/2005
$15,000,000
Accelerated Technologies
9/30/2005
$3,000,000
Bradford Networks
7/14/2005
$17,700,000
Ensemble Discovery
6/30/2005
$11,020,000
ZettaCore
6/30/2005
$6,000,000
AVEO Oncology
6/30/2005
$5,000,100
Mitralign
6/30/2005
$6,700,000
superDimension
6/2/2005
$27,000,000
Trubion Pharmaceuticals
3/31/2005
$12,000,100
Solstice Neurosciences
3/31/2005
$6,000,000
Alantos Pharmaceuticals Holding
3/10/2005
$20,000,000
Applied Spine Technologies
2/23/2005
$15,000,000
Cambrios Technologies
2/1/2005
$12,000,000
Solexa
9/27/2004
$14,400,000
ImpactRx
8/23/2004
$14,300,000
Trubion Pharmaceuticals
7/14/2004
$32,000,000
PowderJect Pharmaceuticals PLC
5/17/2004
$34,500,000
Ensemble Discovery
5/12/2004
$15,000,000
ZettaCore
1/20/2004
$17,500,000
Cellomics
1/9/2004
$5,300,000
Xanthus Pharmaceuticals
12/12/2003
$30,800,000
Elixir Pharmaceuticals
10/13/2003
$40,500,000
Critical Technologies
10/8/2003
$56,000,000
ImpactRx
7/8/2003
$3,000,000
Coherix
4/8/2003
$8,500,000
Targacept
3/19/2003
$60,000,000
Hypnion
3/17/2003
$47,500,000
superDimension
1/26/2003
$13,000,000
Accelerated Technologies
1/6/2003
$32,000,000

 

Investor Contacts

Title
Name
Email & Social
General Partner
Jonathan Fleming
  Jonathan Fleming LinkedIn Profile  Jonathan Fleming Twitter Account  Jonathan Fleming News  Jonathan Fleming on Facebook
General Partner
Matthew Gibbs
  Matthew Gibbs LinkedIn Profile  Matthew Gibbs Twitter Account  Matthew Gibbs News  Matthew Gibbs on Facebook
Partner
Christopher Kim
  Christopher Kim LinkedIn Profile  Christopher Kim Twitter Account  Christopher Kim News  Christopher Kim on Facebook
General Partner
Edmund Olivier
  Edmund Olivier LinkedIn Profile  Edmund Olivier Twitter Account  Edmund Olivier News  Edmund Olivier on Facebook
General Partner
Cornelius Ryan
  Cornelius Ryan LinkedIn Profile  Cornelius Ryan Twitter Account  Cornelius Ryan News  Cornelius Ryan on Facebook
General Partner
Alan Walton
  Alan Walton LinkedIn Profile  Alan Walton Twitter Account  Alan Walton News  Alan Walton on Facebook

 

Funds

No fund closings have been recorded for this company.

 

Portfolio Companies

Oxford Bioscience Partners has invested in the companies below, according to our database records. If we are missing a portfolio company, please let us know.

Tech Company
Accelerated Technologies
Alantos Pharmaceuticals Holding
Applied Spine Technologies
AVEO Oncology
Bradford Networks
Cambridge Endoscopic Devices
Cambrios Technologies
CardioFocus
Cellomics
Claros Diagnostics
Coherex Medical
Coherix
Critical Technologies
Decision Biomarkers
Dicerna Pharmaceuticals
Elixir Pharmaceuticals
Ensemble Discovery
FlowMedica
Glori Energy
Hydrocision
Hypnion
ImpactRx
Intrapace
LUCA Technologies
Melinta Therapeutics
Mitralign
Molecular Biometrics
Pathway Medical Technologies
PINT
PowderJect Pharmaceuticals PLC
Radius Health
Seahorse Bioscience
SmartPill
Solexa
Solstice Neurosciences
superDimension
Targacept
Tragara Pharmaceuticals
Trubion Pharmaceuticals
VaxInnate
Xanthus Pharmaceuticals
Xencor
ZetaRx Biosciences
ZettaCore

 

 

 

 

Browse more venture capital investors:

Oxeon Ventures | Oxford Capital Partners

 

Share this article

 

About Our VC Investors Database

Our data comes from VentureDeal.com, a leading provider of venture capital transaction data.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.